appScorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Glenmark Pharmaceuticals Ltd
GLENMARK
Price Chart
Scorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Glenmark Pharma Gets U.S. FDA Nod To Market Generic Schizophrenia Tablets
14 hours ago•Bloomberg Quint
Glenmark gets USFDA nod to market generic medication to treat schizophrenia
16 hours ago•Business Standard
Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate tablets
18 hours ago•Free Press Journal
Recent EventsAll events
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 20, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine MaleateTablets USP, 5 mg and 10 mg". | Download
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 20, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine MaleateTablets USP, 5 mg and 10 mg". | Download
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2023, titled "Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 toproceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatmentof patients with advanced solid tumors and lymphomas". | Download
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2023, titled "Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 toproceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatmentof patients with advanced solid tumors and lymphomas". | Download
Cash Dividend
Final • Div/Share: ₹ 2.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant